

Octreotide PROMID

### PRELIMINARY SCORE

**CURATIVE**



**NON-CURATIVE**



### ADJUSTMENTS

**Quality of life**



No QoL benefit



**Serious and disabling adverse effects**



**Other adjustments**



Mature data shows no OS advantage and no improved QoL



Octreotide PROMID

### SCORE

**CURATIVE**



Overall Survival / Disease-Free Survival / Pathological Complete Response

**NON-CURATIVE**



Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

**INFORMATION**

Tumour type: Endocrine Tumours  
 Therapeutic Indication: Treatment of patients with advanced neuroendocrine tumours of the midgut or of unknown primary origin where non-midgut sites of origin have been excluded  
 Experimental Arm: Octreotide  
 Control Arm: Placebo



